论文部分内容阅读
Objective:To test the survival ofStaphylococcus aureus (S. aureus) inside lymphocyte that contributes to the pathogenesis of infection and possible anti-inflammatory and antioxidative effect of nanoconjugated vancomycin againstin vivo S. aureus infection in a dose and duration dependent manner.Methods:5×106CFU/mL vancomycin-sensitive S. aureus(VSSA) and vancomycin-resistiveS. aureus (VRSA) were challenged in Swiss male mice for3 days,5 days, 10 days and15days, respectively. Bacteremia and inflammatory parameters were observed to evaluate the duration for development ofVSSA andVRSA infection.100mg/kg bw/day and500 mg/kg bw/day nanoconjugated vancomycin were administrated toVSSA andVRSA infected group for5days. Bacteremia, inflammatory parameters and oxidative stress related parameters were tested to observe the effective dose of nanoconjugated vancomycin againstVSSAandVRSA infection. Nanoconjugated vancomycin was treated at a dose of100 mg/kg bw/day and500 mg/kg bw/day, respectively, toVSSA andVRSA infected group for successive5 days,10 days and 15 days. Bacteremia, inflammatory parameters and oxidative stress related parameters were observed to assess the effective duration of nanoconjugated vancomycin againstVSSAand VRSA infection.Results: The result revealed thatin vivoVSSA andVRSA infection developed after 5 days of challenge by elevating theNO generation in lymphocyte and serum inflammatory markers. Administration with nanoconjugated vancomycin toVSSA andVRSA infected group at a dose of100 mg/kg bw/day and500 mg/kg bw/day, respectively, for successive10 days eliminated bacterimia, decreasedNO generation in lymphocyte, serum inflammatory markers and increased antioxidant enzyme status.Conclusions:These findings suggest,in vivochallenge ofVSSA andVRSA for5 days can produce the highest degree of damage in lymphocyte which can be ameliorated by treatment with nanoconjugated vancomycin for10 successive days.